The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval is an ...

As temperatures drop, many people experience dry, red, and itchy skin, a condition that often worsens in winter.

Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

Live Updates Make sure to refresh this page periodically for updates. Deep Dive into ABBV's Earnings Call 01/01/1970 12:00 am ...

Psoriasis, a painful and uncomfortable inflammatory skin condition that affects millions worldwide, flares up from the ...

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...